Literature DB >> 27807184

Prevalence of lifetime depression in a large hemiplegic migraine cohort.

Mark A Louter1, Nadine Pelzer1, Irene de Boer1, Babette E C Kuijvenhoven1, Willebrordus P J van Oosterhout1, Erik W van Zwet1, Michel D Ferrari1, Gisela M Terwindt2.   

Abstract

OBJECTIVE: To determine the prevalence of depression and determinants associated with depression in a large population of hemiplegic migraine (HM) patients.
METHODS: We conducted a cross-sectional, validated questionnaire study among 89 well-defined HM patients and 235 headache-free controls. The prevalence of lifetime depression and its relation to migraine characteristics was assessed.
RESULTS: HM patients had increased odds for lifetime depression (odds ratio 3.73, 95% confidence interval 2.18-6.38) compared with controls. Use of acute antimigraine medication was associated with lifetime depression.
CONCLUSIONS: Depression is part of the monogenic hemiplegic migraine phenotype. Further studies are needed to elucidate the pathophysiologic role of HM genes in comorbid depression. For now, clinicians should take comorbid depression into consideration when starting prophylactic treatment of HM.
© 2016 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27807184     DOI: 10.1212/WNL.0000000000003376

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  2 in total

Review 1.  Metabolic Aspects of Migraine: Association With Obesity and Diabetes Mellitus.

Authors:  Eduardo Rivera-Mancilla; Linda Al-Hassany; Carlos M Villalón; Antoinette MaassenVanDenBrink
Journal:  Front Neurol       Date:  2021-06-09       Impact factor: 4.003

2.  Dissecting the shared genetic basis of migraine and mental disorders using novel statistical tools.

Authors:  Shahram Bahrami; Guy Hindley; Bendik Slagsvold Winsvold; Kevin S O'Connell; Oleksandr Frei; Alexey Shadrin; Weiqiu Cheng; Francesco Bettella; Linn Rødevand; Ketil J Odegaard; Chun C Fan; Matti J Pirinen; Heidi M Hautakangas; Anders M Dale; Srdjan Djurovic; Olav B Smeland; Ole A Andreassen
Journal:  Brain       Date:  2022-03-29       Impact factor: 13.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.